In DLBCL, Polatuzumab Combo Yields ‘Marked Improvement’ in CR, PFS, OS

Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL.

Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news